Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic — SOCOVID  

COVID19 Clinical Trial

Official title: Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic

Status Completed

Clinical Trial Summary

Ophthalmologic damages secondary to COVID-19 coronavirus infection are little described. The ocular involvement is probably multiple, ranging from pathologies of the anterior segment such as conjunctivitis and anterior uveitis to disorders that threaten vision such as retinitis or optic neuropathy. On the other hand, in addition to this impairment, when patients are hospitalized for acute respiratory failure, complications related to possible resuscitation, medication prescriptions, positioning and oxygenation. COVID-19 itself, has several components: - An apoptotic action of the viral attack which will generate cellular destruction, whether pulmonary, cardiac or renal or maybe ocular - A secondary autoimmune action with the development of major vascular inflammation, possibly reaching the retinal, choroidal, and optic nerve vessels. A secondary "hyper" inflammatory syndrome with flashing hypercytokinemia and multi-organ decompensation is described in 3,7% to 4 ,3% of severe cases. - A thromboembolic action

Clinical Trial Description

Upon discharge from hospital for COVID-19 infection (or during a telephone call for patients already discharged at the start of the study), patients will be informed of the study. An ophthalmology appointment will be given to them between 4 and 6 months after their discharge. During the ophthalmology appointment, the patient's clinical data will be collected during an interview (medical and treatment history, blood group). The patient will benefit from a full ophthalmological examination. ;

Related Conditions & MeSH terms

• COVID19
• Eye Diseases
• Ophthalmopathy
• Respiratory Insufficiency

• NCT number: NCT04387292
• Study type: Interventional
• Source: Fondation Ophtalmologique Adolphe de Rothschild
• Status: Completed
• Phase: N/A
• Start date: September 7, 2020
• Completion date: May 15, 2021